scholarly journals The Effect of Time-dependent Prognostic Factors on Survival of Non-Small Cell Lung Cancer using Bayesian Extended Cox Model

Author(s):  
Vida Pahlevani ◽  
Hossein Fallahzadeh ◽  
Nima Pahlevani ◽  
Abolfazl Nikpour ◽  
Morteza Mohammadzadeh

Background: Lung cancer is one of the most common cancers around the world. The aim of this study was to use Extended Cox Model (ECM) with Bayesian approach to survey the behavior of potential time-varying prognostic factors of Non-small cell lung cancer. Materials and Methods: Survival status of all 190 patients diagnosed with Non-Small Cell lung cancer referring to hospitals in Yazd were recorded from 2009 to 2013 by phone call. We fitted conventional Cox proportional hazards (Cox PH) as well as Bayesian ECM. Inference for estimated risk ratios was based on 90% credible intervals. Log pseudo marginal likelihood criteria (LMPL) was used for model comparison. Statistical computations were based on R language. Results: In this study, 190 patients with non-small cell lung cancer were followed, of whom 160 died because of the disease (84.2%). Median of survival time was 8 ± 0.076 month. After fitting the Cox PH Model, it was determined that the PH assumption was not satisfied for the type of treatment, the disease stage, and pathology status variables (p <0.001). LPML for Cox PH and Bayesian ECM was -431.593 and -401.01, respectively. Estimated hazard ratio curves based on Bayesian ECM showed that the risk ratio for these variables exhibited significant time varying behavior on hazard of lung cancer through follow up time. Conclusion: Based on LMPL, Bayesian ECM was found to have a better fit than Cox PH Model which declares, results from Cox PH should be interpreted with care. Especially, from beginning of the study to about 20 month after, very high risk ratio was estimated for variables whose PH was not satisfying for them.

2021 ◽  
Vol 32 ◽  
pp. S334
Author(s):  
Takashi Inoue ◽  
Hiromi Ishihama ◽  
Taimei Tachibana ◽  
Nobuhiro Imamura ◽  
Yuuto Nonaka ◽  
...  

2020 ◽  
pp. 1-7
Author(s):  
David Conde-Estévez ◽  
Inés Monge-Escartín ◽  
Alejandro Ríos-Hoyo ◽  
Xavier Monzonis ◽  
Daniel Echeverría-Esnal ◽  
...  

1990 ◽  
Vol 8 (6) ◽  
pp. 1042-1049 ◽  
Author(s):  
M P Dearing ◽  
S M Steinberg ◽  
R Phelps ◽  
M J Anderson ◽  
J L Mulshine ◽  
...  

In a study of 411 patients with small-cell lung cancer (SCLC) entered on therapeutic clinical trials between 1973 and 1987, we analyzed whether changes in the prognostic importance of pretreatment factors had occurred during the 14-year time period. After adjusting for other prognostic factors, brain involvement was associated with shorter survival in patients treated before December 1979 (P = .024) but not in patients treated thereafter (P = .54). The patients diagnosed before 1979 had brain metastases documented by radionuclide scan while computed cranial tomography (CCT) was more commonly used after 1979. Patients who had brain metastases diagnosed by radionuclide scan lived a shorter period of time than patients who had the diagnosis made by the more sensitive CCT scan (P = .031). In contrast, Cox proportional hazards modeling showed that liver metastases in patients were associated with shorter survival in patients treated after 1979 (P = .0007) but not in patients treated before then (P = .30). A larger proportion of patients had a routine liver biopsy before 1979 than after 1979 when more patients had the liver staged with less sensitive imaging studies and biochemical parameters. Patients with SCLC whose cancer was confined to the thorax but had medical or anatomic contraindications to intensive chest radiotherapy had similar survival compared with patients with limited-stage SCLC who were treated with combination chemotherapy alone (P = .68). From these data we conclude: (1) the sensitivity of the staging procedures used can affect the impact on survival of cancer involvement of a given site; and (2) patients with cancer confined to their chest with medical or anatomic contraindications to chest radiotherapy do not have a shorter survival than patients with limited-stage disease treated with chemotherapy alone.


CHEST Journal ◽  
2002 ◽  
Vol 122 (3) ◽  
pp. 1037-1057 ◽  
Author(s):  
Michael D. Brundage ◽  
Diane Davies ◽  
William J. Mackillop

2000 ◽  
Vol 70 (4) ◽  
pp. 1168-1171 ◽  
Author(s):  
Abdul R Jazieh ◽  
Mohammad Hussain ◽  
John A Howington ◽  
H.J Spencer ◽  
Muhammad Husain ◽  
...  

2011 ◽  
Vol 18 (1) ◽  
pp. 17-25 ◽  
Author(s):  
Shiro Tanaka ◽  
Kazuhiro Yanagihara ◽  
Satoshi Tamaru ◽  
Satoshi Teramukai ◽  
Toshiyuki Kitano ◽  
...  

2018 ◽  
Vol 10 (2) ◽  
pp. 137-142 ◽  
Author(s):  
Chunhua She ◽  
Ruixia Wang ◽  
Changhong Lu ◽  
Zengfeng Sun ◽  
Peng Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document